Novavax, Inc. (NASDAQ:NVAX) has a 1 Year Target Estimate of $8.74. The stock traded with the volume of 37.77 Million in the last trading session. Novavax, Inc. opened at $2.3 and closed at $2.26 by showing an increase of 3.98%. The Bid price in the last session was $2.39 x 1600 and the Ask price was $2.40 x 5100. (The ask price is what sellers are willing to take for it. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The difference (or spread) goes to the broker/specialist that handles the transaction).
Novavax, Inc. has the Market Capitalization of 636.57 Million. The Stock has its 52-week High of $9.23 and 52-Week Low of $1.16 and it touched its 52-week high on Dec 2, 2015 and 52-Week Low on Sep 16, 2016.
Novavax, Inc. reported its last Earnings on Aug 09 AMC where the company reported Actual EPS of $-0.29/Share whereas, the Analyst Estimated EPS was $-0.25/share. The difference between Actual EPS and Estimated EPS was $-0.04/share. This represented an Earnings Surprise of -16%. The company will report its next earnings on Nov 7 – Nov 11 (Est.).
Some analyst provided their insight on Growth Estimates; Novavax, Inc. has the Current Quarter Earnings Growth rate of -116.7%. The Next Quarter growth is expected to be 13.8%. In the past 5 years, the stock has earnings growth rate of 0% per annum while the Upcoming 5 year’s earnings growth rate is expected to be 0% per annum.
7 number of analysts also provided their insight on Novavax, Inc., where the Average Price Target for the stock is $8.74. They also projected Low Price Target as $1 while High Price Target is set at $17.
A number of analysts rated the stock as well: 5 analysts believe that the stock is a STRONG BUY while 3 reported it as Buy.1 analysts assigned a HOLD rating, 0 said it’s UNDERPERFORM and 0 say that this stock is a SELL.
Novavax, Inc. annual Divided is 0 while it’s Dividend Yield is 0%. The stock has its Price to Earnings (P/E) ratio of 0 and Forward Price to Earnings ratio of 0. The company has its Price to Sales (P/S) ratio of 33.37 where Price to Book (P/B) ratio of 5.73, Price to Cash Per share (P/C) of 1.74 and Price to Free Cash Flow (P/FCF) has a value of 0.
The company has its Return on Assets (ROA) of -56.3 Percent. Return on Equity (ROE) stands at -112.4% and Return on Investment (ROI) displays a value of -53.6%.
The stock is currently trading at Distance from 20-Day simple moving Average of -59.11% whereas, Distance from 50-Day Simple moving average is -64.87 Percent and Distance from 200-Day Simple Moving Average of -61.76 percent.
A look at performance overview of Novavax, Inc. depicts that Performance (Week) is 57.72 percent while Performance Month is -65.79%. Quarterly performance shows a value of -62.52% and Half Year Performance value stands at -54.89%. Yearly performance of the stock has the value of -72.77 percent. Novavax, Inc. has its YTD performance of -71.99 Percent. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging).
Many Insiders have done trades inside the company. The latest trade was made on 20 Sep 2016 where Officer Glenn (Gregory M) did a transaction type “Buy” in which 1000 shares were traded at a price of $1.65. Another insider trade includes Director Douglas (Richard H) who also initiated a transaction in which 100000 shares were traded on 20 Sep 2016 as “Buy”. On 20 Sep 2016 Director McManus (Michael A Jr) traded 30000 shares as “Buy” at $1.61. Chief Financial Officer Phillips (Barclay A) Buy 422 shares on 30 Jul 2016 at the price of $4.29.
The latest Upgrades/Downgrades was done by Research firm Citigroup on 16-Sep-16 who Downgrade the stock from Buy to Neutral. Other firms have also Upgraded/Downgraded the stock. On 16-Sep-16, Wedbush took an action “Downgrade” from Outperform to Neutral. On 16-Sep-16, the stock was Downgrade to Neutral by Ladenburg Thalmann.